Dr. Jacqueline Huang Was Invited for a China Bio-medical Presentation 黃瑋博士獲薦於2019第四屆中國醫藥創新與投資大會發表演講

在香港生物醫藥創新協會推薦之下，黃瑋博士於2019第四屆中國醫藥創新與投資大會分享有關醫藥和生物科技公司跨境併購估值的信息，深入探討香港商業評估的現狀和生物科技公司的估值方法，從業界的商業評估公開諮詢文件到案例分享，從監管的角度到商業評估業界的動態，讓企業和投資人對估值有一個清晰和前瞻性的理解。黃瑋博士表示，對不同發展階段的醫藥和生物科技公司來說，進行估值是非常具挑戰性的工作，唯有選好方法及途徑，還有專業的評估師，才能避開可能的估值陷阱。

Under the recommendation of the Hong Kong Bio-Med Innotech Association, Dr. Jacqueline Huang had delivered a speech on cross-border mergers-and-acquisitions (“M&A”) valuation for biomedical companies and shared the recent industrial development of business valuation in Hong Kong and the valuation methods of biomedical companies in different dimensions - from the industry's public consultation paper to case sharing, and from regulatory perspectives to the dynamics of the industry. Dr. Huang stressed that, the valuation for biomedical companies in different development stages is challenging, and adopting appropriate valuation methods and professional valuers provides a way to prevent possible pitfalls in valuation.

參考網頁: http://www.phirda.com/artilce_20749.html?cId=9